Overview

Tafenoquine in Patients With Mild to Moderate COVID-19

Status:
Active, not recruiting
Trial end date:
2022-02-28
Target enrollment:
Participant gender:
Summary
A clinical study to assess the efficacy and safety of oral tafenoquine compared to placebo in patients with mild to moderate COVID 19 disease.
Phase:
Phase 2
Details
Lead Sponsor:
60 Degrees Pharmaceuticals LLC
Collaborator:
Peachtree BioResearch Solutions Inc.
Treatments:
Tafenoquine